SFCM
GLUE icon

Seven Fleet Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Seven Fleet Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$371K Buy
22,530
+18,530
+463% +$354K 0.12% 90
2025
Q4 		$62.7K Buy
+4,000
New +$53.9K 0.04% 76

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Seven Fleet Capital Management's GLUE Position: Q1 2026 in Review

Seven Fleet Capital Management increased its Monte Rosa Therapeutics (GLUE) stake by 463% in Q1 2026, buying an estimated $354K and bringing the position to 22,530 shares worth $371K. The position accounts for 0.12% of the portfolio, ranked #90.

Seven Fleet Capital Management first reported a position in GLUE in Q4 2025 and has held it in 2 quarters since. 191 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Seven Fleet Capital Management held 22,530 shares of Monte Rosa Therapeutics worth $371K as of Q1 2026.
  • Seven Fleet Capital Management bought 18,530 Monte Rosa Therapeutics shares in Q1 2026, an estimated $354K.
  • Monte Rosa Therapeutics made up 0.12% of Seven Fleet Capital Management's portfolio in Q1 2026, its #90 holding.
  • Seven Fleet Capital Management first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 191 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Seven Fleet Capital Management's 13F filing for Q1 2026, filed 15 May 2026.